Payment overview · 2025
General Payments
$1,231.48
54 reported records · 11 companies
Healthcare provider profile · identity verified
Ellen Michelle Hendricks, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MASON CITY, IL · NPI 1538708086
Verified facts
What the public records show
CMS Open Payments records show Ellen Michelle Hendricks, APN received $1,231.48 in general payments during 2025 across 54 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $267.24 | 21.7% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $238.25 | 19.4% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $220.11 | 17.9% | 17 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $108.77 | 8.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.05 | 8.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.43 | 6.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.06 | 5.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.55 | 4.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.97 | 3.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $45.47 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.58 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,231.48 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $238.25 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $220.11 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $183.81 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $113.63 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.45 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $108.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.43 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.43 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.06 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.97 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $45.47 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 258 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 90 |
| Lisinopril | Lisinopril | 203 | 78 |
| Omeprazole | Omeprazole | 199 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 82 |
| Losartan Potassium | Losartan Potassium | 188 | 76 |
| Prednisone | Prednisone | 164 | 136 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 50 |
| Montelukast Sodium | Montelukast Sodium | 105 | 37 |
| Sertraline Hcl | Sertraline Hcl | 98 | 27 |
| Trazodone Hcl | Trazodone Hcl | 98 | 30 |
| Buspirone Hcl | Buspirone Hcl | 95 | 32 |
| Potassium Chloride | Potassium Chloride | 93 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 45 |
| Pregabalin | Pregabalin | 86 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 37 |
| Meloxicam | Meloxicam | 83 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 38 |
| Alprazolam | Alprazolam | 71 | 27 |
| Furosemide | Furosemide | 70 | 31 |
| Azithromycin | Azithromycin | 69 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 21 |
| Tramadol Hcl | Tramadol Hcl | 62 | 35 |
| Glipizide Er | Glipizide | 60 | 27 |
| Hydrocortisone | Hydrocortisone | 60 | 41 |
| Metformin Hcl | Metformin Hcl | 58 | 28 |
| Allopurinol | Allopurinol | 56 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 24 |
| Lorazepam | Lorazepam | 53 | 20 |
| Famotidine | Famotidine | 52 | 15 |
| Alendronate Sodium | Alendronate Sodium | 51 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 24 |
| Metformin Hcl Er | Metformin Hcl | 49 | 18 |
| Carvedilol | Carvedilol | 48 | 21 |
| Atenolol | Atenolol | 45 | 16 |
| Cephalexin | Cephalexin | 45 | 42 |
| Meclizine Hcl | Meclizine Hcl | 44 | 17 |
| Warfarin Sodium | Warfarin Sodium | 44 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 17 |
| Eliquis | Apixaban | 42 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Mounjaro | Tirzepatide | 39 | 15 |
| Simvastatin | Simvastatin | 38 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 19 |
| Ozempic | Semaglutide | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 11 |
| Baclofen | Baclofen | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 18 |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 15 |
| Bupropion Xl | Bupropion Hcl | 29 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 15 |
| Fluconazole | Fluconazole | 28 | 21 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | 12 |
| Glipizide | Glipizide | 27 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 11 |
| Spironolactone | Spironolactone | 27 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | 11 |
| Synthroid | Levothyroxine Sodium | 23 | 12 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | 11 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Mupirocin | Mupirocin | 17 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | 11 |
| Folic Acid | Folic Acid | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Naproxen | Naproxen | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,231.48 · 54 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, DUPIXENT, EVENITY, FARXIGA, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, Ozempic, PROLIA, QULIPTA, UBRELVY, Wegovy, YUPELRI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error